In contrast to this study, a meta-analysis by Silverii et al. reported that GLP-1R therapy use was associated with a significantly greater risk for overall thyroid cancer in a fixed-effect analysis (44); however, a fragility index of 1 was noted, meaning that it would take only one additional case of thyroid cancer in the comparator group for the association to lose significance. Here, GLP1R is linked to thyroid gland carcinoma.